GlassScriptPhysician profile
Jennifer Penning
NPI 1669897864
$5,142.29
in general payments reported to CMS, 2019-2025
32 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $758 · 2022: $1,333 · 2023: $1,561 · 2024: $844 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,947 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,946.98 |
| Education | $103.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,187.78 | 2021-2025 | |
| Janssen Biotech, INC. | $913.91 | 2021-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $425.88 | 2021-2025 | |
| Genzyme Corporation | $401.13 | 2021-2025 | |
| Amgen INC. | $261.50 | 2021-2024 | Otezla |
| Abbvie INC. | $221.22 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $198.99 | 2021-2022 | |
| Biofrontera INC. | $158.89 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.37 | 2023-2024 | Spevigo, Cyltezo |
| Incyte Corporation | $130.87 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $118.17 | 2021-2024 | Dupixent |
| Arcutis Biotherapeutics, INC. | $115.53 | 2023-2024 | Zoryve |
| Organon LLC | $113.41 | 2024-2025 | Vtama |
| Leo Pharma INC. | $98.90 | 2022-2024 | Adbry |
| Lilly USA, LLC | $95.00 | 2021-2024 | Taltz, Olumiant |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $81.60 | 2022-2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $73.65 | 2022 | |
| Ucb, INC. | $71.93 | 2021-2024 | Cimzia, Bimzelx |
| Kerecis Limited | $51.92 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Kyowa Kirin, INC. | $43.50 | 2023 | Poteligeo |
| Convatec INC. | $25.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $25.25 | 2023 | |
| Bioventus LLC | $24.04 | 2022 | |
| Mylan Institutional INC. | $21.57 | 2023 | Hulio |
| Sun Pharmaceutical Industries INC. | $21.10 | 2024 | |
| Smith+Nephew, INC. | $20.20 | 2024 | Grafix Pl |
| Fresenius Kabi USA, LLC | $19.55 | 2024 | Idacio |
| Organogenesis INC. | $18.75 | 2023 | Puraply |
| Dermavant Sciences, INC. | $18.60 | 2023 | Vtama |
| Merz North America, INC. | $18.42 | 2021 | |
| Verrica Pharmaceuticals INC. | $15.17 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $14.82 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Penning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.